How to Buy Celldex Therapeutics Stock
Celldex Therapeutics Inc
Celldex Therapeutics, Inc. , a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Celldex Therapeutics stock last closed at $20.83, down 0.48% from the previous day, and has decreased 44.33% in one year. It has overperformed other stocks in the Biotechnology industry by 0.33 percentage points. Celldex Therapeutics stock is currently +44.65% from its 52-week low of $14.40, and -55.68% from its 52-week high of $47.00.
There are currently 66.38M shares of CLDX outstanding. The market capitalization of CLDX is $1.38B. In the last 24 hours, 684,578 CLDX shares were traded.
How to Buy Celldex Therapeutics Stock
Wondering how to invest in Celldex Therapeutics stock? Here's how.
- Figure out where to buy Celldex Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you determine where to buy Celldex Therapeutics stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Pick your payment method and add your details.
- Evaluate Celldex Therapeutics stock: The Celldex Therapeutics ticker symbol is CLDX. Is Celldex Therapeutics stock a good investment? Should you buy shares of CLDX? How do CLDX's underlying business fundamentals look? Do top analysts think Celldex Therapeutics is a good buy? Why has CLDX's stock price moved recently? (Hint: Our stock market research tools can help you figure out if CLDX is a good stock to buy).
- Make your CLDX buy order: Decide if you will purchase CLDX shares at the current market price or use a limit order to buy CLDX shares at a specific price.
- Keep an eye on your investment in CLDX: Create a watchlist to keep track of your new investment in Celldex Therapeutics shares.
Step 1: Figure out where to buy Celldex Therapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy CLDX shares.
Our recommended brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world markets: From Technology to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal information so you can invest in CLDX stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to create your new brokerage account.
- Send your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've finished signing up on one of the most highly reviewed stock market apps, you need to deposit funds:
Watch the tutorial below for more details depositing money into your new investment account.
Step 4: Evaluate Celldex Therapeutics stock
After you have decided on the best place to buy Celldex Therapeutics stock, it's very important to evaluate their stock before you buy, so you actually understand the risk as well as the opportunity.
Celldex Therapeutics stock data
CLDX Fundamentals
WallStreetZen was built to help average investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on CLDX's stock page.
Is CLDX stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge CLDX's intrinsic value.
Using relative valuations ratios:
- CLDX could be undervalued based on its P/B ratio of 1.85x, relative to Biotechnology industry P/B ratio of 4.45x
You can access additional valuation research on CLDX's stock here.
CLDX Financials at a glance
Passed Financial Due Diligence Checks:
- Total CLDX debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the CLDX balance sheet.
- There are more short-term assets than long-term liabilities on the CLDX balance sheet.
- CLDX has $725.28M in cash and short term investments. This is sufficient to cover its annual cash burn of $159.70M.
- CLDX has cash burn of 159697000. It has enough cash and short-term investments to cover this for at least one year.
- CLDX has a low debt to equity ratio of 0.06.
Failed Financial Due Diligence Checks:
- CLDX profit margin has gone down from -2,054.8% to -2,248.8% in the past year.
Is it a good time to buy CLDX stock, according to analysts?
Out of 6 sell side analysts who monitor CLDX, the consensus analyst rating on Celldex Therapeutics is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest CLDX Analyst Recommendations
Kristen Kluska, a top 2% analyst from Cantor Fitzgerald reiterates CLDX with a strong buy rating and maintains their CLDX price target from $67.00 to $67.00, on Jan 29, 2025.
You can dive deeper into what analysts are forecasting on the Celldex Therapeutics stock forecast page.
Metrics for Advanced CLDX Traders
Is CLDX Growing Revenue?
Last year, CLDX revenue was $7.02M. During the last five year, CLDX's revenue has gone up by 14.46% per year. This was slower than the Biotechnology industry average of 45.66%.
Learn more about CLDX's earnings and revenue performance here.
Latest Insiders Trades at CLDX
Over the past year, executives and large shareholders at CLDX have bought more shares than they have sold.
Anthony S. Marucci, PRESIDENT CEO of CLDX, was the latest CLDX insider to buy. They bought $308,430.00 worth of CLDX stock on Nov 11, 2024.
Learn more about who owns CLDX shares here.
Does CLDX stock generate passive income?
No, Celldex Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about CLDX
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your CLDX buy order
There are two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally the best for newer investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific price, place a limit order.
Hit the Open button and your broker will execute your order.
If you require additional help investing in stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your investment in CLDX
Now that you own some shares in CLDX, you'll want to stay up-to-date on your company.
Create a watchlist to get notified of important updates regarding your CLDX stock.
CLDX Feed
How to Buy Stock in Celldex Therapeutics
To summarize, here are the 6 steps to buy Celldex Therapeutics stock:
- Figure out where to buy Celldex Therapeutics stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Evaluate Celldex Therapeutics stock
- Make your CLDX buy order
- Keep an eye on your investment in CLDX
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to watch your investment in Celldex Therapeutics, click below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.